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We aimed to assess (1)-whether nuclear b-catenin is a marker of endometrial precancer, and (2)-the diagnostic accuracy
of b-catenin immunohistochemistry in the diﬀerential diagnosis between benign and premalignant endometrial hyper-
plasia (EH), deﬁning criteria for its use. Electronic databases were searched for studies evaluating b-catenin immunohis-
tochemistry in normal endometrium (NE), benign and/or premalignant EH, and endometrioid carcinoma (EC). Odds
ratio (OR; p < 0.05), sensitivity, speciﬁcity, diagnostic OR (DOR), positive and negative likelihood ratios (LR+, LR)
were calculated. Subgroup analyses were based on the classiﬁcation system used (WHO or EIN) and criteria to deﬁne
aberrant b-catenin expression (only nuclear or cytoplasmic/nuclear). Twelve studies with 1510 specimens were included.
Nuclear b-catenin rate signiﬁcantly increased from NE to benign EH (OR = 26.01; p = 0.0002, only in WHO subgroup),
and from benign EH to premalignant EH (OR = 3.89; p = 0.0002; more markedly in EIN subgroup), but not from pre-
malignant EH to EC (OR = 0.78; p = 0.29). Nuclear b-catenin accuracy was very low in WHO subgroup (sensitiv-
ity = 0.40, speciﬁcity = 0.76, LR+ = 1.85, LR = 0.72; DOR = 2.89) and moderate in EIN subgroup (sensitivity = 0.19,
speciﬁcity = 1.00, LR+ = 14.80, LR = 0.83; DOR = 18.14). Cytoplasmic/nuclear b-catenin accuracy was absent in
WHO subgroup (sensitivity = 0.45, speciﬁcity = 0.54, LR+ = 1.01, LR = 1.01; DOR = 0.99) and low in EIN subgroup
(sensitivity = 0.57, speciﬁcity = 0.86, LR+ = 3.63, LR = 0.51; DOR = 8.30). Considering nuclear expression and using
EIN system, b-catenin immunohistochemistry might be reliable as rule-in test for diagnosis of endometrial precancer,
with perfect speciﬁcity and moderate overall accuracy.
Key words: Atypical endometrial hyperplasia; endometrial hyperplasia without atypia; endometrial intraepithelial
neoplasia; endometrial precancer.
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b-catenin is a key protein in Wnt signaling pathway
and is normally expressed on the cellular mem-
brane, where it links cell-cell adherens junctions to
the cytoskeleton. When Wnt pathway is activated,
b-catenin accumulates in the cytoplasm and then
migrates into the nucleus, where it binds to tran-
scription factors of the LEF/TCF family. While
Wnt-b-catenin pathway plays a physiological role
in embryo development and cells proliferation, its
pathologic activation can lead to cancerous
transformation (1–3). In this respect, Wnt-b-catenin
pathway is known to be involved in endometrial
carcinogenesis, with speciﬁc regard to endometrioid
adenocarcinoma and its precursor endometrial
hyperplasia (EH) (2–4). In this ﬁeld, the scientiﬁc
interest in b-catenin has recently increased, since
mutations in its codifying gene CTNNB1 have
shown an independent prognostic value in endome-
trial cancer, delineating a separate molecular sub-
group (3, 5).
Great interest has also been given to b-catenin
assessment in the precancerous phase (6–17). InReceived 14 March 2019. Accepted 23 July 2019
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particular, b-catenin has been one of the most
important markers studied to diﬀerentiate between
premalignant EH and benign EH caused by unop-
posed action of estrogens (18). To date, the gold
standard for such diﬀerential diagnosis is histologic
examination, with two possible classiﬁcation sys-
tems: the World Health Organization (WHO) sys-
tem, based on the presence of cytologic atypia, and
the endometrial intraepithelial neoplasia (EIN) sys-
tem, based on several morphologic parameters (19–
23). However, histologic examination has several
issues such as low reproducibility and possibility of
artifact changes, ambiguous features, or tissue inad-
equacy (24–28).
Although several studies assessed b-catenin
expression by immunohistochemistry on EH speci-
mens, the results are conﬂicting, and the activation
of Wnt pathway also occurs in normal proliferative
endometrium, consequently to the action of estro-
gens (2, 6). Therefore, the actual usefulness of b-
catenin in this ﬁeld was never determined.
Thus, aims of our study were:
1. to deﬁne whether nuclear expression of b-catenin
is a marker of endometrial precancer, by assess-
ing its expression in normal endometrium (NE),
benign hyperplasia (EH), premalignant EH, and
endometrioid carcinoma (EC), evaluating how
the results change according to the histologic
classiﬁcation system used (WHO or EIN);
2. to deﬁne the diagnostic accuracy of b-catenin in
diﬀerentiating premalignant EH from benign
EH, assessing how the accuracy is inﬂuenced by
the criteria used to deﬁne b-catenin pattern as
aberrant (i.e., only nuclear or even cytoplasmic
accumulation).
METHODS
Study protocol
The study protocol was designed a priori, and
methods for electronic search, study selection, risk
of bias assessment, data extraction, and data analy-
sis were deﬁned. All review stages were conducted
independently by two authors (AT, AR), and all
disagreements were resolved by discussion with a
third author (GS).
The study was reported according to the Pre-
ferred Reporting Item for Systematic Reviews and
Meta-analyses (PRISMA) statement (29).
Search strategy
MEDLINE, EMBASE, Web of Sciences, Scopus,
ClinicalTrial.gov, OVID, Cochrane Library, and
Google Scholar were searched for relevant articles
from the inception to January 2019, by using a
combination of the following text words and all
their synonyms found on Medical SubHeading
(MeSH) vocabulary: ‘endometrial hyperplasia’; ‘en-
dometrial cancer’; ‘endometrial intraepithelial neo-
plasia’; ‘EIN’; ‘precancer’; ‘premalignant’;
‘precursor’; ‘b-catenin’; ‘beta-catenin’; ‘nuclear’;
‘Wnt pathway’; ‘marker’; ‘biomarker’; ‘immunohis-
tochemistry’; ‘immunohistochemical’. Abstracts of
all relevant references found were also reviewed.
Study selection
All peer-reviewed, prospective or retrospective stud-
ies, assessing immunohistochemical expression of b-
catenin on histological specimen of premalignant
EH (atypical EH/endometrial intraepithelial neo-
plasia) and/or benign EH (EH without atypia/be-
nign EH) were included in the systematic review.
The following exclusion criteria, deﬁned a priori,
were adopted:
1. data on b-catenin expression not extractable;
2. no EH data;
3. no distinction between benign and premalignant
EH;
4. case reports and reviews;
5. overlapping patient data with a study already
included.
Risk of bias assessment
The revised Quality Assessment of Diagnostic Accu-
racy Studies (QUADAS-2) (30) was adapted to the
included studies, and four domains related to risk of
bias were assessed in each study: (i) patient selection
(if the patients were selected consecutive, or at least
inclusion criteria and period of enrollment were
reported); (ii) index test (if criteria for assessment of
b-catenin were speciﬁed), (iii) reference test (if histo-
logic classiﬁcation criteria were speciﬁed), (iv) ﬂow
and timing (if all patients were assessed with the
same tests; if all patients were assessed with both
index and reference tests). Authors’ judgments were
categorized as ‘low risk’, ‘high risk’, or ‘unclear risk
of bias’. Concerns about applicability (i.e., if study
methods did not suit the aim of our meta-analysis)
were also assessed for the domains 1, 2, and 3.
Data extraction and analysis
Statistical association of b-catenin with histologic
categories
Data were extracted from the included studies with-
out any modiﬁcations. For each study, 2 9 2 con-
tingency tables were prepared, reporting two
dichotomous qualitative variables:
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1. b-catenin expression (‘nuclear’ vs ‘non-nuclear’);
2. histologic category (benign EH vs NE; premalig-
nant EH vs benign EH; EC vs premalignant
EH).
For the studies that did not dichotomize b-cate-
nin expression, data were extracted by using the
following criteria:
1. for the studies using a semi-quantitative scale (1–
3) to grade the intensity b-catenin nuclear stain-
ing, the presence of an intensity at least moderate
(grade 2) was considered as ‘nuclear expression’,
since it has been suggested that a weak nuclear
expression of b-catenin is non-speciﬁc and may
be caused by hormonal action (3).
2. for the studies assessing the rate of cells showing
b-catenin nuclear staining, the presence of at
least a minimum percentage (1%) was consid-
ered as ‘nuclear expression’.
Data regarding EH categories were extracted by
using the following criteria:
1. for the studies using the WHO classiﬁcation, atyp-
ical EH (simple or complex) was considered as
‘premalignant EH’, while EH without atypia (sim-
ple or complex) was considered as ‘benign EH’;
2. for the studies using the EIN classiﬁcation, EH
classiﬁed as ‘EIN’ was considered as ‘premalig-
nant EH’, while EH classiﬁed as ‘benign hyper-
plasia’ was considered as ‘benign EH’.
Statistical association was assessed by using odds
ratio (OR), with 95% conﬁdence interval (CI); a p-
value < 0.05 was considered signiﬁcant. OR was
calculated for each study and as pooled estimate
and reported graphically on a forest plot.
Statistical heterogeneity among studies was
assessed using the inconsistency index (I2): Hetero-
geneity was considered insigniﬁcant for I2 < 25%,
low for I2 < 50%, moderate for I2 < 75%, and high
for I2 ≥ 75%. In case of I2 ≥ 50%, a random eﬀect
model was preferred; otherwise, a ﬁxed-eﬀect model
was adopted.
A subgroup analysis was performed according to
the classiﬁcation system used (WHO vs EIN).
Diagnostic accuracy in diﬀerentiating between
benign and premalignant EH
Beta-catenin expression was the index test, while
EH morphology was the reference standard.
EH specimens with b-catenin nuclear expression
were considered as ‘true positive’ when they showed
premalignant morphology, and ‘false positive’ when
they showed benign morphology. On the other
hand, EH without b-catenin nuclear expression was
considered as ‘true negative’ when they showed
benign morphology and ‘false negative’ when they
showed premalignant morphology.
Diagnostic accuracy was assessed as sensitivity,
speciﬁcity, positive likelihood ratio (LR+), negative
likelihood ratio (LR), and diagnostic OR (DOR),
with 95% CI. DOR was used to quantity the over-
all diagnostic accuracy, as follows: DOR ≤ 1: no
accuracy; 1 < DOR < 3: very low accuracy;
3 ≤ DOR < 10: low accuracy; 10 ≤ DOR < 25:
moderate accuracy; 25 ≤ DOR < 100: high accu-
racy; DOR ≥ 100: very high accuracy. A random
eﬀect model was planned a priori, since a signiﬁcant
heterogeneity is expected in meta-analyses of diag-
nostic accuracy (31).
Statistical analyses were performed using Review
Manager 5.3 (Copenhagen: The Nordic Cochrane
Centre, Cochrane Collaboration, 2014) and Meta-
DiSc version 1.4 (Clinical Biostatistics Unit, Ramon
y Cajal Hospital, Madrid, Spain).
RESULTS
Selection and characteristics of the studies
Out of eighteen studies assessed for eligibility, 4
(32–35) were excluded because of non-extractable
data and 2 (36, 37) because of the absence of EH
specimens. Twelve observational studies (6–17) were
ﬁnally included in the systematic review, with a
total of 270 NE, 312 benign EH, 303 premalignant
EH, and 625 EC. The ﬂow diagram of the process
of study selection is reported in Figure S1.
Eight studies adopted the WHO classiﬁcation
system and 4 the EIN system. Nine studies consid-
ered only a nuclear expression of b-catenin as posi-
tive, two studies evaluated separately nuclear and
cytoplasmic expression, and 3 studies lumped
together nuclear expression and strong cytoplasmic
expression.
Characteristics of the included studies are shown
in Table 1.
Risk of bias assessment
Authors’ judgements regarding risk of bias are
summarized in Figure S2.
For the patient selection domain, 6 studies were
considered at low risk of bias, since they included
consecutive patients, or speciﬁed at least inclusion
criteria and period of enrollment, while the other 6
were considered at unclear risk because the inclu-
sion method was not fully speciﬁed. Concerns
about applicability were raised for two studies [se-
lection restricted to EH or EC conservatively trea-
ted (10); selection of EH with squamous morular
metaplasia (11)].
For the index test domain, 11 studies were con-
sidered at low risk since they reported in detail the
method to interpret immunostaining, while the
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remaining study was considered at unclear risk
because immunohistochemical data were reported
approximatively. Concerns about applicability were
raised for two studies, since they did not aim to
speciﬁcally assess the expression of b-catenin in the
nucleus.
For the reference test domain, all studies were con-
sidered at low risk because they referred to the two
gold standard classiﬁcation systems (WHO and EIN).
For the ﬂow and timing domain, all studies were
considered at low risk since all patients were
assessed using the same index and reference test,
and the histological specimens are not inﬂuenced
by the timing.
No further concerns about applicability were found.
Meta-analysis
Association
Nuclear expression of b-catenin was signiﬁcantly
more common in benign EH than in NE
(OR = 26.01, 95% CI 4.73–143.02; p = 0.0002) in
the WHO subgroup; in the EIN subgroup, no case
of nuclear expression of b-catenin was reported in
benign EH or NE, not allowing a comparison
(Fig. 1).
Nuclear b-catenin was signiﬁcantly more com-
mon in premalignant EH than in benign EH in the
overall analysis (OR = 3.89, 95% CI 1.90–7.98;
p = 0.0002); as well as in the WHO subgroup
(OR = 2.58, 95% CI 1.16–5.75; p = 0.02) and in
the EIN subgroup (OR = 19.65, 95% CI 2.33–
165.82; p = 0.0006) (Fig. 2).
No signiﬁcant diﬀerence was found between pre-
malignant EH and EC (OR = 0.78, 95% CI 0.50–
1.23; p = 0.29); the EIN subgroup analysis was not
feasible due to the presence of only one available
study (Fig. 3).
Diagnostic accuracy
In the WHO subgroup, sensitivity and speciﬁcity of
nuclear expression of b-catenin in diagnosing
endometrial precancer were 0.40 (95% CI, 0.28–
0.53) and 0.76 (95% CI, 0.65–0.84), respectively,
with LR+ and LR of 1.85 (95% CI, 0.79–4.31)
and 0.72 (95% CI, 0.59–0.89), respectively; the
overall accuracy was very low, with a DOR of 2.89
(95% CI, 1.00–8.39) (Fig. 4).
In the EIN subgroup, sensitivity and speciﬁcity
of nuclear expression of b-catenin in diagnosing
endometrial precancer were 0.19 (95% CI, 0.10–
0.31) and 1.00 (95% CI, 0.96–1.00), respectively,
with LR+ and LR of 14.80 (95% CI, 1.91–
114.60) and 0.83 (95% CI, 0.67–1.02), respectively,
and a moderate diagnostic accuracy (DOR = 18.14,
95% CI 2.22–148.5) (Fig. 5).
Considering the criterion ‘cytoplasmic and/or
nuclear expression’, b-catenin showed sensitiv-
ity = 0.45 (95% CI, 0.32–0.59), speciﬁcity = 0.54
(95% CI, 0.44–0.64), LR+=1.01 (95% CI, 0.71–
1.42), LR- = 1.01 (95% CI, 0.76–1.36) and no
diagnostic accuracy (DOR = 0.99, 95% CI, 0.51–
1.89) in the WHO subgroup (Fig. 4), and sensi-
tivity = 0.57 (95% CI 0.42–0.71), speci-
ﬁcity = 0.86 (95% CI, 0.77–0.92), LR+=3.63
(95% CI, 2.15–6.14), LR = 0.51 (95% CI, 0.29–
0.91), and low diagnostic accuracy (DOR = 8.30,
95% CI, 3.60–19.1) in the EIN subgroup
(Fig. 5).
DISCUSSION
Main findings and interpretation
Our analysis showed that nuclear expression of b-
catenin was signiﬁcantly associated with both
WHO and EIN criteria of premalignancy. No
Table 1. Characteristics of the included studies
Year First
author
Country Period of
enrollment
System
adopted
Sample
size
Normal Hyperplastic
TOT ↑ nucl TOT ↑ nucl
1999 Nei Japan n.r. WHO 80 30 0 0 14 8 8
2001 Saegusa Japan 1988–1999 WHO 409 141 n.r. 0 37 n.r. 4
2002 Ashihara Japan n.r. WHO 45 – – – 17 n.r. 7
2003 Moreno
Bueno
Spain n.r. WHO 146 – – – – – –
2003 Saegusa Japan 1988–2000 WHO 24 – – – – – –
2005 Brachtel USA,
Spain
n.r. WHO 24 – – – – – –
2007 Norimatsu Japan 1998–2005 EIN 90 20 n.r. 0 32 n.r. 0
2009 Liao China n.r. WHO 146 15 n.r. 0 14 n.r. 1
2010 Xiong China 2001–2006 EIN 117 10 0 0 59 5 0
2013 Li China 2008–2010 EIN 101 10 0 0 40 9 n.r.
2016 Senol Turkey 2007–2014 WHO 279 30 n.r. n.r. 99 44 n.r.
2018 Strickland USA n.r. EIN 49 14 0 0 – – –
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diﬀerence was found between premalignant EH and
EC, while signiﬁcant diﬀerence between NE and
benign EH was found only for the WHO criteria.
The criterion ‘only nuclear expression’ of b-catenin
showed very low accuracy using WHO criteria, and
moderate accuracy using EIN criteria. On the other
hand, ‘cytoplasmic and/or nuclear expression’
showed no accuracy using WHO criteria and low
accuracy using EIN criteria.
These ﬁndings support that nuclear b-catenin is a
marker of endometrial neoplasia. This was not a
foregone conclusion. In fact, since Wnt-b-catenin
signaling is stimulated by estradiol, an unopposed
estrogen action leads to a constitutive activation of
this pathway (2); therefore, a nuclear expression of
b-catenin might have been expected in benign EH.
However, as we discussed in our previous study, it
seems that hormonal action may only lead to a
weak nuclear expression of b-catenin, which
appears as a light brown nuance. On the other
hand, a moderate-to-strong nuclear expression cor-
relates with mutations in the exon 3 of CTNNB1
(b-catenin gene), particularly in endometrial speci-
mens (3, 6, 38). Our current study tried to eliminate
Premalignant Malignant Immunostaining interpretation Antibody manufacturer
TOT ↑ nucl TOT ↑ nucl
6 4 4 30 9 9 Intensity grade Transduction Lab. (USA)
32 n.r. 10 199 n.r. 65 Stained cells rate Transduction Lab. (USA)
8 n.r. 3 20 n.r. 8 Intensity grade Transduction Lab. (USA)
20 n.r. 4 126 n.r. 31 Combined score Transduction Lab. (USA)
5 n.r. 2 19 n.r. 12 Stained cells rate Transduction Lab. (USA)
24 n.r. 15 – – – Intensity grade Transduction Lab. (USA)
38 n.r. 10 – – – Dichotomous Novocastra (UK)
37 n.r. 12 80 n.r. 18 Stained cells rate Transduction Lab. (USA)
24 10 2 24 14 0 Stained cells rate Maixin-Biotech. (CHN)
25 18 n.r. 26 25 n.r. Dichotomous Neomarkers Inc. (USA)
49 21 n.r. 101 76. n.r. Stained cells rate Cell Marque (USA)
35 6 n.r. – – – Comparison with background Dako (DK)
Fig. 1. Forest plot reporting graphically odds ratio for b-catenin nuclear expression in benign endometrial hyperplasia
(EH) vs normal endometrium (NE).
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such confounding factor by considering only a
nuclear expression of b-catenin at least moderate.
In the second place, our results might support
the better reliability of EIN criteria in diagnosing
precancer. We found that, in the EIN subgroup, no
cases of b-catenin nuclear expression were found
among benign EH, suggesting that EIN criteria had
correctly classiﬁed them as benign; by contrast,
Fig. 3. Forest plot reporting graphically odds ratio for b-catenin nuclear expression in endometrioid carcinoma (EC) vs
premalignant endometrial hyperplasia (EH).
Fig. 2. Forest plot reporting graphically odds ratio for b-catenin nuclear expression in premalignant endometrial hyper-
plasia (EH) vs benign EH.
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nuclear b-catenin was observed in a signiﬁcant
proportion of EH categorized as benign by the
WHO criteria. Furthermore, the association of
nuclear b-catenin with premalignant EH was stron-
ger in the EIN subgroup than in the WHO sub-
group. In our previous studies, we found that also
the expression of PAX2 and Bcl2 correlated better
with EIN criteria than WHO criteria (26, 27); on
the other hand, no diﬀerence was found for PTEN,
although it appeared overall non-speciﬁc (28, 39, 40).
We hypothesized that the main cause of the discrep-
ancy between WHO and EIN system might lie in the
former WHO category of ‘complex non-atypical
EH’. Such category would fall in the benign category
according to the current WHO system, while about
half of them meet EIN criteria for precancer (41–43).
The relevance of nuclear b-catenin as a marker
of endometrial precancer calls into question
whether b-catenin may be clinically applicable in
the diﬀerential diagnosis of EH. The analysis of
diagnostic accuracy was conceived to address this
issue. Consistently with the previously presented
results, in the WHO subgroup the accuracy was
very low. On the other hand, moderate accuracy
was found using EIN criteria, with a low sensitivity
but a perfect speciﬁcity.
Fig. 4. Forest plots reporting graphically diagnostic accuracy metrics of immunohistochemistry for b-catenin in the diﬀer-
ential diagnosis between benign and premalignant hyperplasia according to WHO criteria.
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In spite of the moderate accuracy, such a low
sensitivity makes b-catenin immunohistochemistry
inadequate as a stand-alone diagnostic test. Accord-
ing to guidelines, EH diagnosed as benign do not
always need a treatment and may be managed with
observation alone (44). A little sensitive diagnostic
test would miss many patients at risk of cancer. We
tried to improve sensitivity by considering also a
cytoplasmic accumulation as positive test; unfortu-
nately, despite the increase in sensitivity, speciﬁcity
decreased, resulting in an overall low accuracy. The
low sensitivity appears as an intrinsic problem, since
several diﬀerent molecular pathways are involved in
endometrial carcinogenesis; therefore, it is unlikely
that only one marker may perfectly diﬀerentiate
between benign and premalignant (4, 18, 27, 28).
On the other hand, given its perfect speciﬁcity, b-
catenin immunohistochemistry might be highly reli-
able as a rule-in test for diagnosis of endometrial
precancer. In fact, as hysterectomy is the standard
treatment for premalignant EH (21, 22, 44), a
highly speciﬁc test may avoid the risk of a severe
overtreatment.
In our previous study, we found that also Bcl-2
loss of expression was a highly speciﬁc but little
sensitive marker of endometrial precancer (26). The
issue of the low sensitivity might be resolved by
integrating several speciﬁc immunohistochemical
markers into a diagnostic panel. Given the recent
developments regarding the impact of genetics on
the prognosis of endometrial cancer, the need for a
molecular deﬁnition of endometrial neoplastic sam-
ples has been growing (4, 5, 45). In the near future,
prognostic immunohistochemical markers could
allow a customized approach based on the malignant
potential of EH, choosing not only between progestin
and hysterectomy, but also among diﬀerent conserva-
tive approaches [e.g., progestin alone or combined
with hysteroscopic resection (46, 47)]. Thus, the
costs for additional immunohistochemistry would
Fig. 5. Forest plots reporting graphically diagnostic accuracy metrics of immunohistochemistry for b-catenin in the diﬀer-
ential diagnosis between benign and premalignant hyperplasia according to EIN criteria.
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be justiﬁed in order to reduce both overtreatment
and undertreatment. In this regard, since mutations
in the exon 3 of CTNNB1 were found to bear prog-
nostic value in endometrial cancer (29), a prognostic
role of b-catenin may also be hypothesized in EH.
Remarkably, compared to other molecules involved
in endometrial carcinogenesis, little is known about
the impact of b-catenin on the conservative manage-
ment of EH (48–50). Further studies are necessary in
this ﬁeld.
Strength and limitations
To the best of our knowledge, this study is the ﬁrst
meta-analysis assessing the relevance of b-catenin in
EH. We deﬁned the association between nuclear
expression of b-catenin and premalignant features
in EH and how this association is inﬂuenced by the
classiﬁcation system adopted. Furthermore, we
deﬁned the diagnostic accuracy of b-catenin
immunohistochemistry in the diﬀerential diagnosis
between benign and premalignant EH, assessing
diﬀerent criteria to interpret b-catenin staining.
The major limitation for our results may lie in the
low number of studies included in the subgroup
analysis. Minor limitation might be the low repro-
ducibility of histologic criteria for EH and diﬀer-
ences in the interpretation of immunohistochemistry.
CONCLUSION
A moderate-to-strong nuclear expression of b-cate-
nin appears as a little sensitive, but perfectly speci-
ﬁc marker of endometrial precancer. Considering
even cytoplasmic expression might improve sensitiv-
ity, although with lower speciﬁcity and lower over-
all accuracy. Moreover, the expression pattern of b-
catenin supports the higher reliability of the EIN
system compared to the WHO system.
Despite being inadequate as a stand-alone diag-
nostic test, b-catenin immunohistochemistry may be
a highly reliable rule-in test for diagnosis of endome-
trial precancer. Furthermore, b-catenin might be
included in a panel of speciﬁc immunohistochemical
markers, overcoming the low sensitivity. Given its
recently found prognostic value in endometrial can-
cer, the possibility of a prognostic and/or predictive
role of b-catenin in EH should be considered. Fur-
ther studies are necessary in this ﬁeld.
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Figure S1. Flow diagram of studies identiﬁed in the
systematic review (Prisma template [Preferred
Reporting Item for Systematic Reviews and Meta-
analyses]).
Figure S2. Assessment of risk of bias. Summary of
risk of bias for each study; Plus sign: low risk of
bias; minus sign: high risk of bias; question mark:
unclear risk of bias.
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